1887
Volume 2014, Issue 2
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile, expression and action of vasoactive substances released by the endothelium have been identified in patients with PAH. Of these, endothelin-1 (ET-1) is of particular interest since it is known to be an extremely powerful vasoconstrictor and also involved in vascular remodelling. Identification of ET-1 as a target for pharmacological intervention has lead to the discovery of a number of compounds that can block the receptors via which ET-1 mediates its effects. This review sets out the evidence in support of a role for ET-1 in the onset and progression of the disease and reviews the data from the various clinical trials of ET-1 receptor antagonists for the treatment of PAH.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.29
2014-09-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/2/gcsp.2014.29.html?itemId=/content/journals/10.5339/gcsp.2014.29&mimeType=html&fmt=ahah

References

  1. [1]. Simonneau   G., , Robbins   IM., , Beghetti   M., , Channick   RN., , Delcroix   M., , Denton   CP., , Elliott   CG., , Gaine   SP., , Gladwin   MT., , Jing   ZC., , Krowka   MJ., , Langleben   D., , Nakanishi   N., , Souza   R. . Updated clinical classification of pulmonary hypertension. . Journal of the American College of Cardiology.   2009; ;54: 1 Suppl : S43– S54 .
    [Google Scholar]
  2. [2]. Peacock   AJ., , Murphy   NF., , McMurray   JJ., , Caballero   L., , Stewart   S. . An epidemiological study of pulmonary arterial hypertension. . The European respiratory journal.   2007; ;30: 1 : 104– 109 .
    [Google Scholar]
  3. [3]. Sitbon   O., , Lascoux-Combe   C., , Delfraissy   JF., , Yeni   PG., , Raffi   F., , De Zuttere   D., , Gressin   V., , Clerson   P., , Sereni   D., , Simonneau   G. . Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. . American journal of respiratory and critical care medicine.   2008; ;177: 1 : 108– 113 .
    [Google Scholar]
  4. [4]. Channick   RN., , Simonneau   G., , Sitbon   O., , Robbins   IM., , Frost   A., , Tapson   VF., , Badesch   DB., , Roux   S., , Rainisio   M., , Bodin   F., , Rubin   LJ. . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. . Lancet.   2001; ;358: 9288 : 1119– 1123 .
    [Google Scholar]
  5. [5]. Hachulla   E., , Gressin   V., , Guillevin   L., , Carpentier   P., , Diot   E., , Sibilia   J., , Kahan   A., , Cabane   J., , Francès   C., , Launay   D., , Mouthon   L., , Allanore   Y., , Tiev   KP., , Clerson   P., , de Groote   P., , Humbert   M. . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. . Arthritis and rheumatism.   2005; ;52: 12 : 3792– 3800 .
    [Google Scholar]
  6. [6]. Mukerjee   D., , St George   D., , Coleiro   B., , Knight   C., , Denton   CP., , Davar   J., , Black   CM., , Coghlan   JG. . Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. . Annals of the rheumatic diseases.   2003; ;62: 11 : 1088– 1093 .
    [Google Scholar]
  7. [7]. Machado   RF., , Gladwin   MT. . Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. . Chest.   2010; ;137: 6 Suppl : 30S– 38S .
    [Google Scholar]
  8. [8]. Fonseca   GH., , Souza   R., , Salemi   VM., , Jardim   CV., , Gualandro   SF. . Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. . The European respiratory journal.   2012; ;39: 1 : 112– 118 .
    [Google Scholar]
  9. [9]. Barst   RJ. . Pulmonary hypertension: past, present and future. . Annals of thoracic medicine.   2008; ;3: 1 : 1– 4 .
    [Google Scholar]
  10. [10]. Tuder   RM., , Marecki   JC., , Richter   A., , Fijalkowska   I., , Flores   S. . Pathology of pulmonary hypertension. . Clinics in chest medicine.   2007; ;28: 1 : 23– 42, vii .
    [Google Scholar]
  11. [11]. Montani   D., , Günther   S., , Dorfmüller   P., , Perros   F., , Girerd   B., , Garcia   G., , Jaïs   X., , Savale   L., , Artaud-Macari   E., , Price   LC., , Humbert   M., , Simonneau   G., , Sitbon   O. . Pulmonary arterial hypertension. . Orphanet journal of rare diseases.   2013; ;8: 1 : 97 .
    [Google Scholar]
  12. [12]. McLaughlin   VV., , Archer   SL., , Badesch   DB., , Barst   RJ., , Farber   HW., , Lindner   JR., , Mathier   MA., , McGoon   MD., , Park   MH., , Rosenson   RS., , Rubin   LJ., , Tapson   VF., , Varga   J. . ACCF/AHA expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. . Journal of the American College of Cardiology.   2009; ;53: 17 : 1573– 1619 .
    [Google Scholar]
  13. [13]. Luu   TN., , Chester   AH., , O'Neil   GS., , Tadjkarimi   S., , Yacoub   MH. . Effects of vasoactive neuropeptides on human saphenous vein. . British heart journal.   1992; ;67: 6 : 474– 477 .
    [Google Scholar]
  14. [14]. Dzimiri   N., , Chester   AH., , Allen   SP., , Duran   C., , Yacoub   MH. . Vascular reactivity of arterial coronary artery bypass grafts – implications for their performance. . Clinical cardiology.   1996; ;19: 3 : 165– 171 .
    [Google Scholar]
  15. [15]. Naeije   R., , Chesler   N. . Pulmonary circulation at exercise. . Comprehensive Physiology.   2012; ;2: 1 : 711– 741 .
    [Google Scholar]
  16. [16]. McLaughlin   VV., , McGoon   MD. . Pulmonary arterial hypertension. . Circulation.   2006; ;114: 13 : 1417– 1431 .
    [Google Scholar]
  17. [17]. Christman   BW., , McPherson   CD., , Newman   JH., , King   GA., , Bernard   GR., , Groves   BM., , Loyd   JE. . An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. . The New England journal of medicine.   1992; ;327: 2 : 70– 75 .
    [Google Scholar]
  18. [18]. Tuder   RM., , Cool   CD., , Geraci   MW., , Wang   J., , Abman   SH., , Wright   L., , Badesch   D., , Voelkel   NF. . Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. . American journal of respiratory and critical care medicine.   1999; ;159: 6 : 1925– 1932 .
    [Google Scholar]
  19. [19]. Mitchell   JA., , Ali   F., , Bailey   L., , Moreno   L., , Harrington   LS. . Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. . Experimental physiology.   2008; ;93: 1 : 141– 147 .
    [Google Scholar]
  20. [20]. Ghofrani   HA., , Wiedemann   R., , Rose   F., , Olschewski   H., , Schermuly   RT., , Weissmann   N., , Seeger   W., , Grimminger   F. . Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. . Annals of internal medicine.   2002; ;136: 7 : 515– 522 .
    [Google Scholar]
  21. [21]. Galiè   N., , Ghofrani   HA., , Torbicki   A., , Barst   RJ., , Rubin   LJ., , Badesch   D., , Fleming   T., , Parpia   T., , Burgess   G., , Branzi   A., , Grimminger   F., , Kurzyna   M., , Simonneau   G., , Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. . Sildenafil citrate therapy for pulmonary arterial hypertension. . The New England journal of medicine . 2005; ;353: 20 : 2148– 2157 .
    [Google Scholar]
  22. [22]. Galiè   N., , Brundage   BH., , Ghofrani   HA., , Oudiz   RJ., , Simonneau   G., , Safdar   Z., , Shapiro   S., , White   RJ., , Chan   M., , Beardsworth   A., , Frumkin   L., , Barst   RJ., , Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. . Tadalafil therapy for pulmonary arterial hypertension. . Circulation.   2009; ;119: 22 : 2894– 2903 .
    [Google Scholar]
  23. [23]. Fraisse   A., , Wessel   DL. . Acute pulmonary hypertension in infants and children: cGMP-related drugs. . Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.   2010; ;11: 2 Suppl : S37– S40 .
    [Google Scholar]
  24. [24]. Mathew   R. . Pulmonary hypertension: current therapy and future prospects. . Cardiovascular & hematological agents in medicinal chemistry.   2011; ;9: 3 : 165– 182 .
    [Google Scholar]
  25. [25]. Inoue   A., , Yanagisawa   M., , Kimura   S., , Kasuya   Y., , Miyauchi   T., , Goto   K., , Masaki   T. . The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. . Proceedings of the National Academy of Sciences of the United States of America.   1989; ;86: 8 : 2863– 2867 .
    [Google Scholar]
  26. [26]. Luscher   TF., , Barton   M. . Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. . Circulation.   2000; ;102: 19 : 2434– 2440 .
    [Google Scholar]
  27. [27]. Masaki   T. . The discovery of endothelins. . Cardiovascular research.   1998; ;39: 3 : 530– 533 .
    [Google Scholar]
  28. [28]. Benatti   L., , Fabbrini   MS., , Patrono   C. . Regulation of endothelin-1 biosynthesis. . Annals of the New York Academy of Sciences.   1994; ;714: : 109– 121 .
    [Google Scholar]
  29. [29]. Dorfman   DM., , Wilson   DB., , Bruns   GA., , Orkin   SH. . Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. . The Journal of biological chemistry.   1992; ;267: 2 : 1279– 1285 .
    [Google Scholar]
  30. [30]. Morey   AK., , Razandi   M., , Pedram   A., , Hu   RM., , Prins   BA., , Levin   ER. . Oestrogen and progesterone inhibit the stimulated production of endothelin-1. . The Biochemical journal.   1998; ;330: Pt 3 : 1097– 1105 .
    [Google Scholar]
  31. [31]. Denault   JB., , Claing   A., , D'Orléans-Juste   P., , Sawamura   T., , Kido   T., , Masaki   T., , Leduc   R. . Processing of proendothelin-1 by human furin convertase. . FEBS letters.   1995; ;362: 3 : 276– 280 .
    [Google Scholar]
  32. [32]. Valdenaire   O., , Lepailleur-Enouf   D., , Egidy   G., , Thouard   A., , Barret   A., , Vranckx   R., , Tougard   C., , Michel   JB. . A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. . European journal of biochemistry/FEBS.   1999; ;264: 2 : 341– 349 .
    [Google Scholar]
  33. [33]. Galie   N., , Manes   A., , Branzi   A. . The endothelin system in pulmonary arterial hypertension. . Cardiovascular research.   2004; ;61: 2 : 227– 237 .
    [Google Scholar]
  34. [34]. Frelin   C., , Guedin   D. . Why are circulating concentrations of endothelin-1 so low?.   Cardiovascular research.   1994; ;28: 11 : 1613– 1622 .
    [Google Scholar]
  35. [35]. Simonson   MS. . Endothelins: multifunctional renal peptides. . Physiological reviews.   1993; ;73: 2 : 375– 411 .
    [Google Scholar]
  36. [36]. Sauvageau   S., , Thorin   E., , Caron   A., , Dupuis   J. . Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. . Experimental biology and medicine.   2006; ;231: 6 : 840– 846 .
    [Google Scholar]
  37. [37]. Thorin   E., , Clozel   M. . The cardiovascular physiology and pharmacology of endothelin-1. . Advances in pharmacology.   2010; ;60: : 1– 26 .
    [Google Scholar]
  38. [38]. Pollock   DM., , Keith   TL., , Highsmith   RF. . Endothelin receptors and calcium signaling. . FASEB journal: official publication of the Federation of American Societies for Experimental Biology.   1995; ;9: 12 : 1196– 1204 .
    [Google Scholar]
  39. [39]. Ohlstein   EH., , Arleth   A., , Bryan   H., , Elliott   JD., , Sung   CP. . The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. . European journal of pharmacology.   1992; ;225: 4 : 347– 350 .
    [Google Scholar]
  40. [40]. Hirata   Y., , Emori   T., , Eguchi   S., , Kanno   K., , Imai   T., , Ohta   K., , Marumo   F. . Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. . The Journal of clinical investigation.   1993; ;91: 4 : 1367– 1373 .
    [Google Scholar]
  41. [41]. Shichiri   M., , Kato   H., , Marumo   F., , Hirata   Y. . Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. . Hypertension.   1997; ;30: 5 : 1198– 1203 .
    [Google Scholar]
  42. [42]. Dupuis   J., , Goresky   CA., , Fournier   A. . Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. . Journal of applied physiology.   1996; ;81: 4 : 1510– 1515 .
    [Google Scholar]
  43. [43]. Dupuis   J., , Stewart   DJ., , Cernacek   P., , Gosselin   G. . Human pulmonary circulation is an important site for both clearance and production of endothelin-1. . Circulation.   1996; ;94: 7 : 1578– 1584 .
    [Google Scholar]
  44. [44]. Matsumoto   H., , Suzuki   N., , Onda   H., , Fujino   M. . Abundance of endothelin-3 in rat intestine, pituitary gland and brain. . Biochemical and biophysical research communications.   1989; ;164: 1 : 74– 80 .
    [Google Scholar]
  45. [45]. Lal   H., , Williams   KI., , Woodward   B. . Chronic hypoxia differentially alters the responses of pulmonary arteries and veins to endothelin-1 and other agents. . European journal of pharmacology.   1999; ;371: 1 : 11– 21 .
    [Google Scholar]
  46. [46]. Kemp   BK., , Smolich   JJ., , Cocks   TM. . Evidence for specific regional patterns of responses to different vasoconstrictors and vasodilators in sheep isolated pulmonary arteries and veins. . British journal of pharmacology.   1997; ;121: 3 : 441– 450 .
    [Google Scholar]
  47. [47]. Lambers   C., , Roth   M., , Zhong   J., , Campregher   C., , Binder   P., , Burian   B., , Petkov   V., , Block   LH. . The interaction of endothelin-1 and TGF-beta1 mediates vascular cell remodeling. . PloS one.   2013; ;8: 8 : e73399 .
    [Google Scholar]
  48. [48]. Seccia   TM., , Belloni   AS., , Kreutz   R., , Paul   M., , Nussdorfer   GG., , Pessina   AC., , Rossi   GP. . Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. . Journal of the American College of Cardiology.   2003; ;41: 4 : 666– 673 .
    [Google Scholar]
  49. [49]. Shi-Wen   X., , Denton   CP., , Dashwood   MR., , Holmes   AM., , Bou-Gharios   G., , Pearson   JD., , Black   CM., , Abraham   DJ. . Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. . The Journal of investigative dermatology.   2001; ;116: 3 : 417– 425 .
    [Google Scholar]
  50. [50]. Jozsef   L., , Khreiss   T., , Fournier   A., , Chan   JS., , Filep   JG. . Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes. . British journal of pharmacology.   2002; ;135: 5 : 1167– 1174 .
    [Google Scholar]
  51. [51]. Ishikawa   T., , Yanagisawa   M., , Kimura   S., , Goto   K., , Masaki   T. . Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. . The American journal of physiology.   1988; ;255: 4 Pt 2 : H970– H973 .
    [Google Scholar]
  52. [52]. Ishikawa   T., , Yanagisawa   M., , Kimura   S., , Goto   K., , Masaki   T. . Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. . Pflugers Archiv: European journal of physiology.   1988; ;413: 1 : 108– 110 .
    [Google Scholar]
  53. [53]. Giaid   A., , Yanagisawa   M., , Langleben   D., , Michel   RP., , Levy   R., , Shennib   H., , Kimura   S., , Masaki   T., , Duguid   WP., , Stewart   DJ. . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. . The New England journal of medicine.   1993; ;328: 24 : 1732– 1739 .
    [Google Scholar]
  54. [54]. Bressollette   E., , Dupuis   J., , Bonan   R., , Doucet   S., , Cernacek   P., , Tardif   JC. . Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. . Chest.   2001; ;120: 3 : 809– 815 .
    [Google Scholar]
  55. [55]. Stewart   DJ., , Levy   RD., , Cernacek   P., , Langleben   D. . Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?.   Annals of internal medicine.   1991; ;114: 6 : 464– 469 .
    [Google Scholar]
  56. [56]. Filep   JG., , Bodolay   E., , Sipka   S., , Gyimesi   E., , Csipo   I., , Szegedi   G. . Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. . Circulation.   1995; ;92: 10 : 2969– 2974 .
    [Google Scholar]
  57. [57]. Uguccioni   M., , Pulsatelli   L., , Grigolo   B., , Facchini   A., , Fasano   L., , Cinti   C., , Fabbri   M., , Gasbarrini   G., , Meliconi   R. . Endothelin-1 in idiopathic pulmonary fibrosis. . Journal of clinical pathology.   1995; ;48: 4 : 330– 334 .
    [Google Scholar]
  58. [58]. Giaid   A., , Michel   RP., , Stewart   DJ., , Sheppard   M., , Corrin   B., , Hamid   Q. . Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. . Lancet.   1993; ;341: 8860 : 1550– 1554 .
    [Google Scholar]
  59. [59]. Jia   B., , Zhang   S., , Chen   Z., , Li   Z., , Li   X., , Hui   W., , Ye   M. . Plasma endothelin 1 concentrations in children with congenital heart defects. . Minerva pediatrica.   1998; ;50: 4 : 99– 103 .
    [Google Scholar]
  60. [60]. Gorenflo   M., , Bettendorf   M., , Brockmeier   K., , Ulmer   HE. . Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. . Zeitschrift fur Kardiologie.   2000; ;89: 11 : 1000– 1008 .
    [Google Scholar]
  61. [61]. Thomson   JR., , Machado   RD., , Pauciulo   MW., , Morgan   NV., , Humbert   M., , Elliott   GC., , Ward   K., , Yacoub   M., , Mikhail   G., , Rogers   P., , Newman   J., , Wheeler   L., , Higenbottam   T., , Gibbs   JS., , Egan   J., , Crozier   A., , Peacock   A., , Allcock   R., , Corris   P., , Loyd   JE., , Trembath   RC. . Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. . Journal of medical genetics.   2000; ;37: 10 : 741– 745 .
    [Google Scholar]
  62. [62]. International PPHC , Lane   KB., , Machado   RD., , Pauciulo   MW., , Thomson   JR., , Phillips   JA 3rd., , Loyd   JE., , Nichols   WC., , Trembath   RC. . Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. . Nature genetics.   2000; ;26: 1 : 81– 84 .
    [Google Scholar]
  63. [63]. Machado   RD., , Pauciulo   MW., , Thomson   JR., , Lane   KB., , Morgan   NV., , Wheeler   L., , Phillips   JA 3rd., , Newman   J., , Williams   D., , Galiè   N., , Manes   A., , McNeil   K., , Yacoub   M., , Mikhail   G., , Rogers   P., , Corris   P., , Humbert   M., , Donnai   D., , Martensson   G., , Tranebjaerg   L., , Loyd   JE. . BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. . American journal of human genetics.   2001; ;68: 1 : 92– 102 .
    [Google Scholar]
  64. [64]. Deng   Z., , Morse   JH., , Slager   SL., , Cuervo   N., , Moore   KJ., , Venetos   G., , Kalachikov   S., , Cayanis   E., , Fischer   SG., , Barst   RJ., , Hodge   SE., , Knowles   JA. . Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. . American journal of human genetics.   2000; ;67: 3 : 737– 744 .
    [Google Scholar]
  65. [65]. Rubin   LJ., , Roux   S. . Bosentan: a dual endothelin receptor antagonist. . Expert opinion on investigational drugs.   2002; ;11: 7 : 991– 1002 .
    [Google Scholar]
  66. [66]. Rubin   LJ., , Badesch   DB., , Barst   RJ., , Galie   N., , Black   CM., , Keogh   A., , Pulido   T., , Frost   A., , Roux   S., , Leconte   I., , Landzberg   M., , Simonneau   G. . Bosentan therapy for pulmonary arterial hypertension. . The New England journal of medicine.   2002; ;346: 12 : 896– 903 .
    [Google Scholar]
  67. [67]. Weber   C., , Banken   L., , Birnboeck   H., , Schulz   R. . Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. . Journal of clinical pharmacology.   1999; ;39: 8 : 847– 854 .
    [Google Scholar]
  68. [68]. Humbert   M., , Nunes   H., , Sitbon   O., , Parent   F., , Herve   P., , Simonneau   G. . Risk factors for pulmonary arterial hypertension. . Clinics in chest medicine.   2001; ;22: 3 : 459– 475 .
    [Google Scholar]
  69. [69]. Barst   RJ., , Ivy   D., , Dingemanse   J., , Widlitz   A., , Schmitt   K., , Doran   A., , Bingaman   D., , Nguyen   N., , Gaitonde   M., , van Giersbergen   PL. . Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. . Clinical pharmacology and therapeutics.   2003; ;73: 4 : 372– 382 .
    [Google Scholar]
  70. [70]. Sitbon   O., , Gressin   V., , Speich   R., , Macdonald   PS., , Opravil   M., , Cooper   DA., , Fourme   T., , Humbert   M., , Delfraissy   JF., , Simonneau   G. . Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. . American journal of respiratory and critical care medicine.   2004; ;170: 11 : 1212– 1217 .
    [Google Scholar]
  71. [71]. Galie   N., , Beghetti   M., , Gatzoulis   MA., , Granton   J., , Berger   RM., , Lauer   A., , Chiossi   E., , Landzberg   M. . Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. . Circulation.   2006; ;114: 1 : 48– 54 .
    [Google Scholar]
  72. [72]. Wilkins   MR., , Paul   GA., , Strange   JW., , Tunariu   N., , Gin-Sing   W., , Banya   WA., , Westwood   MA., , Stefanidis   A., , Ng   LL., , Pennell   DJ., , Mohiaddin   RH., , Nihoyannopoulos   P., , Gibbs   JS. . Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. . American journal of respiratory and critical care medicine.   2005; ;171: 11 : 1292– 1297 .
    [Google Scholar]
  73. [73]. Barst   RJ., , Langleben   D., , Badesch   D., , Frost   A., , Lawrence   EC., , Shapiro   S., , Naeije   R., , Galie   N., , STRIDE-2 Study Group. . Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. . Journal of the American College of Cardiology.   2006; ;47: 10 : 2049– 2056 .
    [Google Scholar]
  74. [74]. Segal   ES. . Tracleer (bosentan).   2006; ; . Available from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153430.pdf  .
    [Google Scholar]
  75. [75]. Dingemanse   J., , van Giersbergen   PL. . Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. . Clinical pharmacokinetics.   2004; ;43: 15 : 1089– 1115 .
    [Google Scholar]
  76. [76]. Motte   S., , McEntee   K., , Naeije   R. . Endothelin receptor antagonists. . Pharmacology & therapeutics.   2006; ;110: 3 : 386– 414 .
    [Google Scholar]
  77. [77]. Denton   CP., , Pope   JE., , Peter   HH., , Gabrielli   A., , Boonstra   A., , van den Hoogen   FH., , Riemekasten   G., , De Vita   S., , Morganti   A., , Dölberg   M., , Berkani   O., , Guillevin   L., , TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators. . Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. . Annals of the rheumatic diseases.   2008; ;67: 9 : 1222– 1228 .
    [Google Scholar]
  78. [78]. Valerio   CJ., , Coghlan   JG. . Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. . Vascular health and risk management.   2009; ;5: : 607– 619 .
    [Google Scholar]
  79. [79]. Cheng   JW. . Ambrisentan for the management of pulmonary arterial hypertension. . Clinical therapeutics.   2008; ;30: 5 : 825– 833 .
    [Google Scholar]
  80. [80]. Barst   RJ. . A review of pulmonary arterial hypertension: role of ambrisentan. . Vascular health and risk management.   2007; ;3: 1 : 11– 22 .
    [Google Scholar]
  81. [81]. Galie   N., , Olschewski   H., , Oudiz   RJ., , Torres   F., , Frost   A., , Ghofrani   HA., , Badesch   DB., , McGoon   MD., , McLaughlin   VV., , Roecker   EB., , Gerber   MJ., , Dufton   C., , Wiens   BL., , Rubin   LJ., , Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. . Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. . Circulation.   2008; ;117: 23 : 3010– 3019 .
    [Google Scholar]
  82. [82]. Galie   N., , Badesch   D., , Oudiz   R., , Simonneau   G., , McGoon   MD., , Keogh   AM., , Frost   AE., , Zwicke   D., , Naeije   R., , Shapiro   S., , Olschewski   H., , Rubin   LJ. . Ambrisentan therapy for pulmonary arterial hypertension. . Journal of the American College of Cardiology.   2005; ;46: 3 : 529– 535 .
    [Google Scholar]
  83. [83]. Opitz   CF., , Ewert   R., , Kirch   W., , Pittrow   D. . Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?.   Eur Heart J.   2008; ;29: 16 : 1936– 1948 .
    [Google Scholar]
  84. [84]. Barst   RJ., , Langleben   D., , Frost   A., , Horn   EM., , Oudiz   R., , Shapiro   S., , McLaughlin   V., , Hill   N., , Tapson   VF., , Robbins   IM., , Zwicke   D., , Duncan   B., , Dixon   RA., , Frumkin   LR., , STRIDE-1 Study Group. . Sitaxsentan therapy for pulmonary arterial hypertension. . American journal of respiratory and critical care medicine.   2004; ;169: 4 : 441– 447 .
    [Google Scholar]
  85. [85]. Benza   RL., , Barst   RJ., , Galie   N., , Frost   A., , Girgis   RE., , Highland   KB., , Strange   C., , Black   CM., , Badesch   DB., , Rubin   L., , Fleming   TR., , Naeije   R. . Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. . Chest.   2008; ;134: 4 : 775– 782 .
    [Google Scholar]
  86. [86]. Langleben   D., , Cacoub   P. . A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. . European journal of clinical investigation.   2009; ;39 Suppl 2: : 27– 31 .
    [Google Scholar]
  87. [87]. Benza   RL., , Mehta   S., , Keogh   A., , Lawrence   EC., , Oudiz   RJ., , Barst   RJ. . Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. . The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation.   2007; ;26: 1 : 63– 69 .
    [Google Scholar]
  88. [88]. Boniface   S., , Reynaud-Gaubert   M. . Endothelin receptor antagonists – their role in pulmonary medicine. . Revue des maladies respiratoires.   2011; ;28: 8 : e94– e107 .
    [Google Scholar]
  89. [89]. Agency TEM . Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury.   2010; ; . Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/news_and_events/news/2010/12/news_detail_001161.jsp&mid = WC0b01ac058004d5c1
    [Google Scholar]
  90. [90]. Bolli   MH., , Boss   C., , Binkert   C., , Buchmann   S., , Bur   D., , Hess   P., , Iglarz   M., , Meyer   S., , Rein   J., , Rey   M., , Treiber   A., , Clozel   M., , Fischli   W., , Weller   T. . The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. . Journal of medicinal chemistry.   2012; ;55: 17 : 7849– 7861 .
    [Google Scholar]
  91. [91]. Iglarz   M., , Binkert   C., , Morrison   K., , Fischli   W., , Gatfield   J., , Treiber   A., , Weller   T., , Bolli   MH., , Boss   C., , Buchmann   S., , Capeleto   B., , Hess   P., , Qiu   C., , Clozel   M. . Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. . The Journal of pharmacology and experimental therapeutics.   2008; ;327: 3 : 736– 745 .
    [Google Scholar]
  92. [92]. Sidharta   PN., , van Giersbergen   PL., , Halabi   A., , Dingemanse   J. . Macitentan: entry-into-humans study with a new endothelin receptor antagonist. . European journal of clinical pharmacology.   2011; ;67: 10 : 977– 984 .
    [Google Scholar]
  93. [93]. Sidharta   PN., , van Giersbergen   PL., , Dingemanse   J. . Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. . Journal of clinical pharmacology.   2013; ;53: 11 : 1131– 1138 .
    [Google Scholar]
  94. [94]. Sitbon   O., , Morrell   N. . Pathways in pulmonary arterial hypertension: the future is here. . European respiratory review: an official journal of the European Respiratory Society.   2012; ;21: 126 : 321– 327 .
    [Google Scholar]
  95. [95]. Hatano   M., , Yao   A., , Kinugawa   K., , Hirata   Y., , Nagai   R. . Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. . International heart journal.   2011; ;52: 4 : 233– 239 .
    [Google Scholar]
  96. [96]. Hoeper   MM., , Faulenbach   C., , Golpon   H., , Winkler   J., , Welte   T., , Niedermeyer   J. . Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. . The European respiratory journal.   2004; ;24: 6 : 1007– 1010 .
    [Google Scholar]
  97. [97]. Benza   RL., , Rayburn   BK., , Tallaj   JA., , Pamboukian   SV., , Bourge   RC. . Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. . Chest.   2008; ;134: 1 : 139– 145 .
    [Google Scholar]
  98. [98]. Akagi   S., , Matsubara   H., , Miyaji   K., , Ikeda   E., , Dan   K., , Tokunaga   N., , Hisamatsu   K., , Munemasa   M., , Fujimoto   Y., , Ohe   T. . Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. . Circulation journal: official journal of the Japanese Circulation Society.   2008; ;72: 7 : 1142– 1146 .
    [Google Scholar]
  99. [99]. Maki   H., , Yao   A., , Inaba   T., , Shiga   T., , Hatano   M., , Kinugawa   K., , Yamashita   T., , Aizawa   T., , Nagai   R. . Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. . International heart journal.   2011; ;52: 5 : 323– 326 .
    [Google Scholar]
  100. [100]. Tapson   VF., , Torres   F., , Kermeen   F., , Keogh   AM., , Allen   RP., , Frantz   RP., , Badesch   DB., , Frost   AE., , Shapiro   SM., , Laliberte   K., , Sigman   J., , Arneson   C., , Galiè   N. . Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. . Chest.   2012; ;142: 6 : 1383– 1390 .
    [Google Scholar]
  101. [101]. Jing   ZC., , Parikh   K., , Pulido   T., , Jerjes-Sanchez   C., , White   RJ., , Allen   R., , Torbicki   A., , Xu   KF., , Yehle   D., , Laliberte   K., , Arneson   C., , Rubin   LJ. . Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. . Circulation.   2013; ;127: 5 : 624– 633 .
    [Google Scholar]
  102. [102]. Seed   A., , Kuc   RE., , Maguire   JJ., , Hillier   C., , Johnston   F., , Essers   H., , de Voogd   HJ., , McMurray   J., , Davenport   AP. . The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. . Life sciences.   2012; ;91: 13-14 : 743– 748 .
    [Google Scholar]
  103. [103]. Parvanova   A., , van der Meer   IM., , Iliev   I., , Perna   A., , Gaspari   F., , Trevisan   R., , Bossi   A., , Remuzzi   G., , Benigni   A., , Ruggenenti   P., , Daglutril in Diabetic Nephropathy Study Group. . Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. . The lancet Diabetes & endocrinology.   2013; ;1: 1 : 19– 27 .
    [Google Scholar]
  104. [104]. Kohan   DE., , Rossi   NF., , Inscho   EW., , Pollock   DM. . Regulation of blood pressure and salt homeostasis by endothelin. . Physiological reviews.   2011; ;91: 1 : 1– 77 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.29
Loading
/content/journals/10.5339/gcsp.2014.29
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error